Abstract
Greystone Research Associates is pleased to announce the publication of a new
market study. Transdermal CNS Therapeutics: Products Pipeline Candidates,
Markets and Forecasts is a comprehensive evaluation and analysis of the
technology, products and participants providing the driving force behind this
evolving segment of the therapeutic neurology sector.
The study is designed to provide drug company decision makers, CNS product
managers, drug delivery developers, device designers, healthcare marketers,
and supply chain participants with a detailed understanding of the economics,
technologies, treatable conditions, and commercial opportunities for
transdermal CNS drug delivery. Provider organization business managers,
healthcare administrators and investors will also benefit from this study.
Drug Products and Candidates for a Growing Clinical Need
Unlike several other disease segments, progress toward curative medicine for
neurological and related central nervous system disorders has remained
elusive. The result is a therapeutic segment that relies heavily on control of
symptoms and palliative care. This disappointing picture is being exacerbated
by disease trends that are increasing the morbidity and mortality associated
with CNS ailments in the general population. These trends include the growing
incidence of neurological disorders associated with longevity and aging, and
significant increases in the number of children diagnosed with autism.
Because diseases of the central nervous system often result in compromised
cognitive and/or motor skills that can increase the level of involuntary
non-compliance with therapeutic protocols, transdermal delivery of drugs
targeting CNS disorders is generally viewed as a method that can increase
patient safety and improve outcomes. In addition to the handful of
FDA-approved transdermal CNS products, more than a dozen companies are
currently pursuing a range of APIs in transdermal delivery systems that target
neurological and CNS conditions. While none of these development-stage
candidates is curative, the benefits they can offer in terms of patient
ease-of-use, product safety and overall quality-of-care are expected to result
in reduced morbidity and more effective symptom management for afflicted
patients.
Feature Summary
- Analyzes and evaluates the global market opportunity for transdermal CNS
prescription therapeutics and assesses the probable impact of evolving
regulatory, economic and demand factors
- Assesses transdermal products approved or in development for the delivery
of therapeutic CNS drugs
- Provides detailed descriptions of CNS treatment segments, market factors,
and business strategies
- Forecasts transdermal CNS drug product demand to 2015 by geographic region
and product segment
- Profiles sector companies, their product development activities, supply
chain partners, business strategies, and collaboration partners
- Evaluates the impact of economic, technology, and regulatory factors on
CNS therapeutics demand
Methodology
Research methodology is based on primary research in the form of in-depth
interviews with key market participants, technology developers, distributors,
industry experts, and market influencers, a list that includes regulatory
officials, industry trade groups, and materials standards organizations.
Primary data is evaluated and normalized against secondary sources including
trade journal articles, technical literature, industry publications, company
data sheets and published information, and statistical data from government
agencies and trade associations.
Forecasts and projections of market demand and future market activity are
derived using standard modeling and statistical techniques.
About Greystone Research Associates
Greystone Research Associates is a medical technology consulting firm focused
on the areas of medical market strategy, product commercialization, venture
development, and market research. We assist medical and healthcare market
participants in achieving their business objectives through the creation of
detailed development strategies, product commercialization programs, and
comprehensive market and technology research and analysis.
Our market research publications are designed, researched and written to
provide timely and insightful information and data on focused market segments,
with the aim of providing market participants with the essential knowledge to
refine and execute their marketing plans and financial targets.
Table of Contents
Executive Summary
- The Current CNS Drug Therapeutics Market
- Unmet Needs in CNS Disease Treatment
- The Opportunity for Transdermal Delivery of CNS Therapeutics
The CNS Therapeutics Market Opportunity
- Changes and Trends in Incidence and Morbidity
- The Demand Picture for CNS Therapeutics
- Competitive Landscape
- Factors Limiting Growth
Transdermal Drug Delivery to the CNS
- Patch Designs and Construction
- Transdermal Patch Manufacturing and Packaging
- The Patch Manufacturing Ecosystem
- CNS Patch Economics
- Passive vs Active Delivery Systems
The Global Market for Transdermal CNS Therapeutics - Disease Segment Analysis
- ADHD
- Alzheimer' s Disease
- Dementia
- Depression
- Migraine
- Nausea
- Parkinson' s Disease
- Restless Leg Syndrome
- Schizophrenia
Transdermal CNS Drug Product Analysis and Market Assessments
- FDA Approved Transdermal CNS Prescription Products
- MAO Inhibitors
- Cholinergic Agents
- Dopamine Agonists
- CNS Stimulants
- 5-HT3 Receptor Antagonists
- Non-FDA Approved Commercial Transdermal CNS Products
- Non-U.S. Regional Product Assessment & Market Impact
- Strategic Factors and Branding Issues
- Development-Stage Transdermal CNS Prescription Products
- AChE Inhibitors
- Cholinergic Agents
- Dopamine Agonists
- 5-HT3 Receptor Antagonists
- Serotonin Agonists
- Other Drug Classes
Transdermal CNS Therapeutics Market Data & Forecasts
Market Factors
- Regulations and Approvals
- Clinical Trials
- Indications Prescribing Guidelines and Off-Label Prescribing
- Rx-to-OTC Switching
- Skin Patch Revenue Models
Market Participant Profiles of Market Participa
